GENE ONLINE|News &
Opinion
Blog

2025-11-29|

Study Explores Neuroprotective Effects of Green Tea Compound EGCG Against Diazinon-Induced Brain Damage

by GOAI
Share To

A recent study has examined the potential neuroprotective effects of epigallocatechin gallate (EGCG), a compound commonly found in green tea, against neurotoxicity caused by diazinon, a widely used pesticide. Researchers Onukak C.E., Femi-Akinlosotu O.M., and Obasa A.A. conducted the investigation to explore how EGCG may mitigate the harmful effects of diazinon through its anti-inflammatory and antioxidant properties.

The study highlights that diazinon exposure is associated with significant neurotoxic effects, which can lead to inflammation and oxidative stress in the brain. The researchers focused on EGCG due to its known bioactive properties, including its ability to combat oxidative damage and reduce inflammation. Their findings suggest that EGCG plays a role in counteracting these harmful processes, potentially offering protection against pesticide-induced neurological damage. Further details about the methodology or specific outcomes were not disclosed in this report.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top